Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Dendritic Cells and Immune Checkpoint Inhibition After Radiotherapy in Unresectable Primary Liver Cancer
NCT03942328Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2019
- Primary completion
- Aug 2030
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Intus in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), sponsored by Mayo Clinic. Started Sep 2019; status: recruiting.
02
Drugs
Intus
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03942328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942328.